Tumor-infiltrating B lymphocytes promote melanoma progression and resistance to therapy

September 19, 2017

In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ("TABs") in melanoma progression and resistance to targeted therapy. This study provides a molecular mechanism that governs the cross-talk between TABs and tumor cells as well as a potential new therapeutic strategy for combating tumors resistant to treatment. The study was published online in Nature Communications.

Advanced is very difficult to treat because even after initially successful treatment, tumors eventually become resistant to conventional and targeted therapies. It is well established that the tumor microenvironment, or the complex of stroma-derived cells and immune cells surrounding cancer cells, plays a role in melanoma progression and therapy resistance. These study results describe how TABs, which account for up to one third of all that infiltrate the tumor, can promote tumor heterogeneity and cancer stem cell-like populations that are associated with drug resistance. In immunity against infections, B-cells and their progeny, the plasma cells, produce antibodies that can eliminate the disease. Antibodies can also be produced against but are rarely effective to eradicate the cancer.

"Our results point to an important cancer-promoting function of tumor-infiltrating B-cells and elucidate the molecular 'conversation' between B-cells and melanoma cells, which eventually favors tumor progression and therapy resistance," said lead researcher Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar Professor and director of The Wistar Institute Melanoma Research Center.

Herlyn, Rajasekharan Somasundaram, Ph.D., Research Assistant Professor in the Molecular and Cellular Oncogenesis Program at Wistar, Stephan N. Wagner, M.D., from the Medical University of Vienna, and colleagues used a co-culture system of melanoma cells and B-cells to evaluate the reciprocal effect of the interaction between these two cell types. By using this approach, they could identify those inflammatory factors produced by B-cells and that were relevant for the interaction and can be used as potential targets for novel therapy. The researchers also analyzed tissue samples from melanoma patients and confirmed the prevalence of TABs in advanced, therapy-resistant tumors tissues. Additionally, these tissues showed increased expression of insulin like growth factor (IGF)-1 and fibroblast growth factor receptor (FGFR)-3, identified as crucial players in the B cell-melanoma cross-talk and potential new therapeutic targets for .

Importantly, the study also included a pilot multicenter clinical trial to evaluate the therapeutic potential of B-cell depletion in therapy-resistant advanced melanoma patients using a monoclonal antibody that specifically binds to CD20, a molecule present on the surface of these cells, thereby causing their death.

"Our results describe a novel mechanism of drug resistance in melanoma induced by tumor-infiltrating B-cells," said Somasundaram, first and one of the corresponding authors of the paper. "This study also provides a clinical basis for developing a novel therapeutic approach for advanced melanoma based on targeting infiltrating B-."

Explore further: Link established between a molecular driver of melanoma and novel therapeutic agent

Related Stories

Link established between a molecular driver of melanoma and novel therapeutic agent

September 7, 2017
Results of a study by The Wistar Institute have described a correlation between a key melanoma signaling pathway and a novel class of drugs being tested in the clinic as adjuvant therapy for advanced melanoma, providing useful ...

Anti-aging gene identified as a promising therapeutic target for older melanoma patients

February 23, 2017
Scientists at The Wistar Institute have shown that an anti-diabetic drug can inhibit the growth of melanoma in older patients by activating an anti-aging gene that in turn inhibits a protein involved in metastatic progression ...

Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

September 11, 2017
T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. Promoting a switch from glucose to ...

Diabetes drug points the way to overcoming drug resistance in melanoma

June 11, 2013
Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current ...

Aging impacts therapeutic response of melanoma cells

April 4, 2016
Cancer risk increases with one's age as accumulated damage to our cells and chronic inflammation occur over time. Now, an international team of scientists led by The Wistar Institute have shown that aged tumor cells in melanoma ...

Researchers discover mechanism leading to BRAF inhibitor resistance in melanoma

June 19, 2015
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining ...

Recommended for you

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.